期刊文献+

过氧化物酶体增殖物激活受体激动剂类药物的致癌性和致癌机制研究进展 被引量:2

Progress of carcinogenesis and possible mechanisms of peroxisome proliferator-activated receptor agonists
下载PDF
导出
摘要 过氧化物酶体增殖物激活受体(PPAR)是一类由配体激活的核转录因子,参与糖类和脂类代谢、炎症反应、细胞生长和分化等过程,以其为靶点的降脂类及抗糖尿病药物已经被开发。PPAR激动剂对动物有致癌性,如一些贝特类PPARα激动剂、噻唑烷二酮类PPARγ激动剂、开发的PPARα/γ双重激动剂和PPARδ激动剂均可使实验动物发生肿瘤。PPARα激动剂的致癌机制同PPARα受体有关,激活受体调节代谢产生脂类异常,也引起过氧化物酶体氧化酶活性增加,产生活性氧导致DNA的损伤。枯否细胞通过NADPH氧化酶产生活性氧促进肝细胞增殖,抑制凋亡。PPARγ激动剂的致癌性与结石形成有关。PPAR激动剂是否对人具有致癌性尚未证实,临床应用仍有致癌风险。本文主要综述PPAR激动剂致癌性和致癌机制研究进展,希望对该类药物的开发有所帮助。 Peroxisome proliferator-activated receptors( PPARs) are ligand-activated nuclear transcription factors,playing an important role in the regulation of glucose and lipids metabolism,inflammation response,proliferation and differentiation. Some drugs targeted on PPARs,such as lipid-lowering and antidiabetic drugs have been developed. Some PPAR agonists were found carcinogenic in animal experiments,including PPARα agonist fibrates,PPARγ agonist thiazolidinediones,PPARα /γ dual agonist compounds,and PPARδ agonist compounds for clinical development. PPARα agonist carcinogenicity is associated with PPAR receptor activation that regulates lipid metabolism,and leads to lipids abnormalities and increase by peroxisome oxidase in reactive oxygen species( ROS),causing DNA damage. Kupffer cells can generate ROS by NADPH oxidase that promotes hepatocyte proliferation and inhibition of apoptosis. PPARγ agonist carcinogenicity is generally caused by bladder stone. The carcinogenicity of PPAR agonists to humans has not been confirmed,but the carcinogenic potential of these drugs cannot be ignored.
出处 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 2014年第3期455-461,共7页 Chinese Journal of Pharmacology and Toxicology
基金 国家科技重大专项(2013ZX09302304)~~
关键词 过氧化物酶体增殖物激活受体激动剂 毒性作用 致癌物 peroxisome proliferators activated receptors agonists toxic actions carcinogens
  • 引文网络
  • 相关文献

参考文献45

  • 1Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species[J].Toxicol Sci, 2005, 87(2):322-327. 被引量:1
  • 2Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study[J].BMJ, 2012, 344:e3645. 被引量:1
  • 3Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer[J].Lancet, 2011, 378(9802):1543-1544. 被引量:1
  • 4Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwan Residents[J].Diabetes Care, 2012, 35(2):278-280. 被引量:1
  • 5Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC. The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone[J].Diabetes Metab J, 2012, 36(5):371-378. 被引量:1
  • 6Barbalat Y, Dombrovskiy VY, Weiss RE. Association between pioglitazone and urothelial bladder cancer[J].Urology, 2012, 80(1):1-4. 被引量:1
  • 7Shukla R, Kalra S. Pioglitazone: Indian perspective[J].Indian J Endocrinol Metab, 2011, 15(4):294-297. 被引量:1
  • 8Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators[J].Biochim Biophys Acta, 2007, 1771(8):1065-1081. 被引量:1
  • 9Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment[J].Trends Endocrinol Metab, 2012, 23(5):205-215. 被引量:1
  • 10罗文艳,刘永学.PPAR受体双重/泛激动剂存在的问题及前景[J].中国新药杂志,2008,17(4):279-282. 被引量:2

二级参考文献22

  • 1ISSEMANN I, GREEN S. Activation of a member of the steroid hormone receptor super family by peroxisome proliferators [ J ]. Nature, 1990,347 ( 6294 ) :645 - 650. 被引量:1
  • 2GUAN Y,BREYER MD. Targeting peroxisome proliferator-activated receptors(PPARs) in kidney and urologic disease [ J ]. Minerva Urol Nefrol, 2002,54 ( 2 ) :65 - 79. 被引量:1
  • 3HUSS JM, KELLY DP. Nuclear receptor signaling and cardiac energetics[ J ]. Circ Res, 2004,95 (6) :568 - 578. 被引量:1
  • 4BALAKUMAR P, ROSE M, GANTI SS, et al. PPAR dual agonist : Are they opening Pandora's BOX? [ J]. Pharmacol Res,2007,56 (2) :91 -98. 被引量:1
  • 5GUAN Y,ZHANG Y,BREYER MD. The role of PPARs in the transcriptional control of cenuar processes [ J ]. Drug News Perspect ,2002,15 ( 3 ) : 147 - 154. 被引量:1
  • 6YU K, BAYONA W, KALLEN CB, et al. Differential activation of peroxisome proliferator activated receptors by eicosanoids [ J]. Biol Chem, 1995,270 (41 ) : 23975 - 23983. 被引量:1
  • 7TENENBAUM A, MOTRO M, FISMAN EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons [ J ]. Cardiovasc Diabetol, 2005,4 ( 1 ) : 1 - 5. 被引量:1
  • 8BARISH GD, NARKAR VA, EVANS RM. PPAR delta: a dagger in the heart of the metabolic syndrome [ J ]. J Clin Invest, 2006,116(3) :590 - 597. 被引量:1
  • 9HENKE BR. Peroxisome proliferator-activated receptor a/γ dual agonists for the treatment of type 2 diabetes [ J ]. Med Chem, 2004,47(17) :4118 -4127. 被引量:1
  • 10POURCET B, FRUCHART JC, STAELS B, et al. Selective PPAR modulators, dual and pan PPAR agonists: muhimodal drugs for the treatment of type2 diabetes and atherosclerosis [ J ]. Expert Opin Emerg Drugs,2006,11 (3) :379 - 401. 被引量:1

共引文献1

同被引文献16

引证文献2

二级引证文献20

;
使用帮助 返回顶部